Testing AMT-676 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called AMT-676 in people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers like colorectal, stomach, or pancreatic cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced solid tumor that cannot be removed by surgery, and standard treatments have stopped working or are not an option for you.
- Your cancer has at least one measurable tumor on a scan.
- You are generally well enough to be up and about (ECOG score 0 or 1), and your doctor expects you to live at least 3 more months.
- You have not had a prior treatment with a drug similar to AMT-676 (a drug that targets the same protein or uses a topoisomerase I inhibitor).
- You do not have cancer that has spread to the brain, a history of severe skin reactions, or active lung inflammation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AMT-116 in people with advanced solid tumors that have not responded to prior treatment. The goal is to see if it is safe and effective.
This study tests an experimental drug AMT-253 in people with advanced solid tumors (like melanoma) that have progressed despite prior treatment. The goal is to see if the drug can help shrink or slow the cancer.
This trial tests a new drug, BTM-3566, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
This trial tests a new drug called HRS-6768 for people with advanced solid tumors that have stopped responding to standard treatments or have no good options. It aims to see if the drug is safe and effective.
This trial tests a new drug called ASN-3186 for people with advanced solid tumors that have not responded to other treatments. It may help those whose tumors have specific genetic changes, like BRCA mutations.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.